- Abstract Number: 1649
B Cell Subset Contribution to Autoantibodies in Lupus
- Abstract Number: 0858
Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)
- Abstract Number: 0476
Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients
- Abstract Number: 1731
Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
- Abstract Number: 0273
Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study
- Abstract Number: 1057
Barriers and Facilitators of Access to Physical Therapy: A Scoping Review
- Abstract Number: 0262
Bartonella Endocarditis as an Important Mimic of ANCA Associated Vasculitis: Results of a Large Single Center Descriptive Analysis
- Abstract Number: 1475
Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
- Abstract Number: 2356
Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
- Abstract Number: 0769
Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica
- Abstract Number: 2644
Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis
- Abstract Number: 1597
Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis
- Abstract Number: 0330
Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
- Abstract Number: 1837
Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment
- Abstract Number: 1906
Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review
- Abstract Number: 0673
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
- Abstract Number: 2664
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
- Abstract Number: 0595
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
- Abstract Number: 0143
Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021
- Abstract Number: 2518
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
- Abstract Number: 0693
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
- Abstract Number: 0149
Beliefs on Self-Management in Rheumatoid Arthritis Compared to Other Chronic Diseases Using the Nationally Representative Medical Expenditure Panel Survey
- Abstract Number: 1554
Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
- Abstract Number: 0665
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
- Abstract Number: 2402
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
- Abstract Number: 1530
Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
- Abstract Number: 1074
Bending the Curve on Inbox Bloat: A Patient Portal Project to Mature-the-Message via Nurse Triage to Reduce Provider Inbox Time
- Abstract Number: 2365
Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
- Abstract Number: 0004
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
- Abstract Number: 0031
Beyond Pain and Inflammation: Intra-articular Liraglutide’s Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone
- Abstract Number: 0191
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
- Abstract Number: 2348
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
- Abstract Number: 0602
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
- Abstract Number: 0591
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
- Abstract Number: 0597
Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
- Abstract Number: 1757
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
- Abstract Number: 2352
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
- Abstract Number: 2368
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
- Abstract Number: 0600
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
- Abstract Number: 0110
Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists
- Abstract Number: 1305
Bingo: A Winning Pediatric Rheumatology Teaching Strategy?
- Abstract Number: 1794
Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus
- Abstract Number: 0401
Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
- Abstract Number: 2523
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
- Abstract Number: 2572
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
- Abstract Number: 0485
Biomarkers for Disease Activity and Response to Treatment in Early Rheumatoid Arthritis: Metabolomics and Machine Learning Analyses in NORD-STAR Cohort
- Abstract Number: 2387
Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
- Abstract Number: 0825
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
- Abstract Number: 0837
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
- Abstract Number: 1806
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
- Abstract Number: 0039
Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum
- Abstract Number: 2420
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
- Abstract Number: 1299
Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development
- Abstract Number: 2509
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
- Abstract Number: 2164
Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase
- Abstract Number: 0215
BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics
- Abstract Number: 0058
Bradykinin Receptor B1 Blockade Suppresses Soluble CD13-Induced Differentiation of Osteoclasts from Monocytes
- Abstract Number: 2625
Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus
- Abstract Number: PP15
Breathing Mindfully and How to Control Anxiety in Lupus Patients
- Abstract Number: 0882
Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
- Abstract Number: 1058
Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
- Abstract Number: 0614
Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient
- Abstract Number: PP13
Bridging the Gap from Pediatric to Adult Rheumatology Care
- Abstract Number: 0179
Bridging the Gap: Enhancing Diversity in Lupus Clinical Trials Through Investigator and Research Staff Engagement
- Abstract Number: 1309
Bridging the Gap: Evaluating Ophthalmology Training Amongst Pediatric Rheumatology Fellows
- Abstract Number: 1777
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
- Abstract Number: 0007
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
- Abstract Number: 1013
Burden of Emergency Department Visits and Their Outcomes Among Patients with Rheumatoid Arthritis: Insights from the Nationwide Emergency Department Sample (NEDS)
ACR Convergence 2024
November 14-19, 2024. Washington, DC.